Member Info for Porter_

88 posts in half a day is a new record for you 😆

Wouldn’t surprise me if orders are still being filled, hence the 2.5 on LSE. Quite a confident open.

There was a bit of a buying frenzy into the close on Friday, so it wouldn’t surprise me if we see more delayed prints or a gap up on open. 3p really isn’t that far away when you think Genflow has been doing 100% gains in a day.

Agree computer, 5-10p seems like a good starting point.

Interesting how traders got locked out last week and are now slamming Genflow, especially bringing up investors who sold their investment over a year ago.

If derampers want to slam the share for their own financial gain and commit market abuse, at least do some credible research 😆

You know you’re onto a good one when the pay per post creatures turn up 👌🏻

Never seen you post about Genflow before so doubt you’re a holder, but appreciate your concern.

Lovely of the rag to be giving Genflow free publicity, helping Genflow’s online presence and Google algorithm.

Genuine shareholders have done their research, hence deciding to help contribute towards the phase 2 dog programme costs.

New updates:

Genflow Biosciences is a UK-based biotechnology company that is developing gene therapies to target the aging process and delay or reduce age-related diseases. The company is publicly listed on the London Stock Exchange (LON: GENF) and has research and development facilities in Belgium.

Technology

SIRT6 gene: The company's therapies are based on a variant of the SIRT6 (Sirtuin-6) gene, which is found in centenarians (people who live to 100 or beyond). Research suggests that increased levels of the SIRT6 gene can promote healthy aging.

AAV vectors: Genflow uses adeno-associated virus (AAV) vectors to deliver copies of the SIRT6 gene variant into cells.

Targeting aging: The company's goal is to extend both "healthspan" and "lifespan" by intervening directly in the aging process.

Product pipeline

Genflow has several product candidates in its pipeline:

GF-1002: An intravenous gene therapy using the SIRT6-centenarian variant for human aging. Preclinical trials are also evaluating its potential for treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), a type of liver disease.

GF-1004: A non-human version of the anti-aging gene therapy developed for veterinary use, specifically for dogs. This is being tested in a clinical trial involving older beagles to evaluate safety and efficacy.

Other candidates: The pipeline also includes GF-1003 for skin treatments, GF-1005 for muscle health, and GF-1006 for ophthalmology conditions like glaucoma.

Recent developments

Positive dog trial results: In October 2025, Genflow reported positive results from its GF-1004 dog aging study. The therapy was safely administered for a second time to elderly beagles, with no observed side effects.

Animal health partnerships: The company has signed confidential disclosure agreements with major animal health companies to explore potential partnerships for its canine therapy.

Regulatory progress: Genflow is moving towards human trials for its aging therapies, with regulatory submissions and clinical studies expected to accelerate.

Financial performance: The company's stock experienced a significant jump in October 2025 following the encouraging results from the dog trial.

Doesn’t surprise me, I worked at a mega Pharma in Belgium a few years back, and they were throwing out billion dollar deals just on hopium, to prevent competitors from getting a sniff at the next potential big thing.

100% NE, see this article where the big pharma are snapping up newly patented tech for $billions, as their existing patents expire, and they shift in a new commercial direction:

https://chemanager-online.com/en/news/biotech-ma-at-4-year-high-as-pharma-faces-expiring-patents

They get one or both patents, that secures the IP which offers asset security for a big Pharma takeover, so the moon jam, the moon :)

Anything could happen next week:

Grant money

New programmes

Patents

Formal offer for dog programme

More companies showing interest on dog programme

New programmes

New TR1’s

Total takeover interest / offer

🍿

Eric confirmed he has 2 NDA’s signed ref the dog pharma programme and is considering both licensing agreements, plus an outright sale of that line. We could hear news of a programme acquisition given both companies seem serious about the programme. Hopefully that will generate significant cash flow for the company, if some form of a deal can be wrapped up.

Hopefully Trump will begin to regulate anti-aging skin care the same way he did CBD.

If that’s the case, the Genflow patents could be worth even more, given the skin care industry is worth a fortune!

After those late prints, I’d say some cheap positions were gained, while others were silly enough to leave the table right before the main show begins 😁

Fully agree money. Expecting more fireworks to follow :)

Https://www.thisismoney.co.uk/money/markets/article-15180653/amp/SMALL-CAP-MOVERS-British-biotech-help-dogs-live-longer-lives.html

Unicorn

The fact they have 2 companies interested in doing a deal with them on the pet pharmaceuticals says all I need to know. Getting my popcorn and fireworks sorted!

Hope so NE. The ATH was 12p on just 2 conception stage programmes.

Genflow now have 5 programmes with multiple compound variants and patient groups that have progressed rapidly, 2 patents in final stages, 2 large pharma with NDA’s looking to do deals, and a number of HNW’s backing the company.

As a minimum, I would love to see Genflow get back to 12p a share to ensure investor value.

Love this:

Genflow aims to introduce a new class of longevity-based treatments into the multi-billion-dollar global animal health market, targeting improved healthspan, vitality, and lifespan in companion and livestock animals.

AI: The livestock industry is worth trillions of dollars globally and billions in individual countries, with figures such as the global value of farmed animals estimated to be between $1.61–$3.3 trillion USD, and the UK's meat industry alone valued at over £12 billion. Specific livestock segments, like the global dairy industry and individual animal markets, also represent significant economic value, with cattle and dairy production being particularly valuable global commodities.

Great observation Key.

It’s worth looking at the companies prospectus, which confirms Vera and the team at Rochester are seeking to bring patented technology to Genflow, focusing on longevity with animals that include mice, beavers and naked mole rats.

Other animals which are noted to provide great research in helping to extend aging and quality of life include whales and jellyfish.

https://genflowbio.com/wp-content/uploads/2022/01/Genflow-Biosciences-Prospectus-FINAL-PDF.pdf